| Document |
Document Title |
|
WO/2020/187965A1 |
The invention relates to an efficient and industrially applicable process for the preparation and purification of allopregnanolone and intermediates thereof without the assistance of column chromatography.
|
|
WO/2020/180661A1 |
This disclosure relates to extracts from chestnut plants and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the leaves of a Castanea plant. In certain embodiments, the disclosur...
|
|
WO/2020/176843A1 |
The present invention generally relates to new compounds for therapeutic uses. In particular, this disclosure relates to novel tetracyclic compounds useful for treatment of cancer, especially castration resistant prostate cancer. Pharmac...
|
|
WO/2020/132504A1 |
Provided herein is a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R2a, R2b, R4a, R4b, R6, R7, R11a, R11b, R16, R17, R3, R5, R19 and RX are defined herein and wherein RY represents optionally substituted he...
|
|
WO/2020/118437A1 |
The present invention relates to new compounds and compositions comprising active ingredient derivatives of testosterone, and novel testosterone derivatives, novel testosterone methods, novel testosterone compositions, novel testosterone...
|
|
WO/2020/104484A1 |
The present invention relates to the synthesis of N-trifluoromethylcarbonyl compounds starting from isothiocyanates, which can be converted into N-trifluoromethylcarbamoyl fluorides or similar compounds, which later on can be derivatized...
|
|
WO/2020/082065A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3, R6a, R6b, R2a, R2b, R4a, R4b, R7a, R7b, R11, R12a, R12b, R16, R21a, R21b, and R21c are defined herein. Also provided here...
|
|
WO/2020/077255A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R15b, R16a and R16b are defined herein. ...
|
|
WO/2020/053509A1 |
The invention relates to a family of analogue compounds of squalamine for their use as a drug, in particular for treating or for preventing mycobacterial infections, in particular tuberculosis. A further aim of the present invention is n...
|
|
WO/2020/051329A1 |
The present disclosure relates to stereodefined polycyclic (e.g., tetracyclic) compounds that contain quaternary centers at one or multiple ring fusions, synthetic methods for preparing such compounds, and methods of using such compounds...
|
|
WO/2019/186444A1 |
The present invention relates to liquid formulations of Abiraterone intended for oral administration. The invention provides suspension and emulsion fom1ulations of Abiraterone and process of preparing such formulations. Further, the inv...
|
|
WO/2019/173499A1 |
Disclosed are compounds suitable for enhancing cancer treatment, for example, a compound of formula (I): (I) wherein R1 is as defined herein. Also disclosed is a method of enhancing the response of cancer cells in a mammal to treatment w...
|
|
WO/2019/165350A1 |
The present invention discloses processes for producing normal alpha olefins, such as 1-hexene, 1-octene, 1-decene, and 1-dodecene in a multistep synthesis scheme from another normal alpha olefin. Also disclosed are reactions for convert...
|
|
WO/2019/129182A1 |
Disclosed is an application of 2β,3α,5α-trihydroxyl androstane-6-ketone and a deuterated compound thereof or pharmaceutically acceptable salts thereof in the preparation of drugs for treating inflammatory reactions of patients. The pr...
|
|
WO/2019/128154A1 |
Provided is a method for synthesizing the 17-position side chain of a steroid drug, wherein same is characterized in using compound I as a starting material, and the 17-position side chain is synthesized by nucleophilic, esterification, ...
|
|
WO/2019/126741A1 |
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...
|
|
WO/2019/113494A1 |
Provided herein is a deuterated compound of Formula (I) Formula (I) or a pharmaceutically acceptable salt thereof, wherein R3a,R5, R6a, R6b, R17, R21a, R21b, Rm, Rn, R16a, R16 b, R7a, R7b, R12a, R12b, R11a R11b, R2a, R2b, R19, R4a, and R...
|
|
WO/2019/098179A1 |
Provided are: a novel internal standard substance that is useful for measuring androgen; a highly selective and sensitive (accurate) method for measuring androgen which is capable of simplifying pretreatment and uses liquid chromatograph...
|
|
WO/2019/070139A1 |
A new crystalline form of anhydrous 17-β-estradiol (estra-l,3,5(10)-triene-3,17β-diol), method of its preparation and its use have been disclosed.
|
|
WO/2019/024920A1 |
The present disclosure provides methods of preparing cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, and novel and useful synthetic intermediates, ...
|
|
WO/2018/197296A1 |
The present invention relates to a process for the synthesis of intermediates of general formula (I): by means of a simultaneous protection and hydrogenation reaction of an intermediate of formula (II), according to the scheme below: Com...
|
|
WO/2018/196883A2 |
Disclosed is a method for preparing 16β-methyl steroid compound, comprising a methylenation reaction and a hydrogenation reduction reaction. Compared to the prior art, the preparation method of the present invention orientedly synthesiz...
|
|
WO/2018/185783A1 |
The present invention provides a single pot process for the synthesis of 19-Norethisterone of Formula (I), comprising contacting 19-Norandostene-3,17-dione of Formula–II with a first base, an organic gas/solution and an acid to obtain ...
|
|
WO/2018/127927A1 |
A system for delivery of drugs, and especially genetic drugs such as siRNA or antisense oligonucleotides (ASO) across biological membranes is provided. It comprises a trans- membrane delivery moiety, energized by the membrane internal el...
|
|
WO/2018/129555A1 |
A method for the treatment of an individual suffering from non-alcoholic steatohepatitis is provided comprising administering to the individual in need of such treatment an effective amount of a compound according to Formula I: wherein: ...
|
|
WO/2018/112512A1 |
An efficient and commercial phosphorylation process of a complex alcohol, such as secondary and tertiary alcohols, with P4O10 at high temperatures, and a product obtained by the process.
|
|
WO/2018/039110A1 |
An estrogen receptor β selective ligand can be a compound according to Structure 1: wherein m is 0, 1, or 2 and R is H, a C1 to C5 alkyl group, vinyl, CF3, CH2CH2F, CH2CHF2, or CH2CF3. A composition (e.g., pharmaceutical or cosmetic com...
|
|
WO/2018/025083A1 |
The described invention relates to small molecule therapeutic compounds capable of reducing the incidence of intracerebral hemorrhage and brain microhemorrhages identified using zebrafish and mouse models of intracerebral hemorrhage and ...
|
|
WO/2018/010932A1 |
The present invention relates to a method of reacting starting materials with an activating group, namely alkanes carrying a leaving group and/or olefins, with carbon dioxide under transition metal catalysis to give carboxyl group-contai...
|
|
WO/2018/013615A1 |
Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R2, R3, R4, R5, R6, R7, R11a, R11b,R12, R16, R17, R19, and ----- are as define...
|
|
WO/2018/013613A1 |
Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a comp...
|
|
WO/2017/211330A1 |
15β-substituted derivatives of estrone of general formula I wherein R1, R2, R3, R4, R5 are independently selected from the group consisting of: C1-C4 alkyl, C1-C4 alkoxy, C1-C4 halogenalkyl, halogen, COOR6 wherein R6 is C1-C4 alkyl; H, ...
|
|
WO/2017/192668A1 |
Disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery. In particular, disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery based o...
|
|
WO/2017/173358A1 |
Compounds are provided according to Formula (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein A, R1, and R5 are as defined herein. Compounds of the present invention are contemplated use...
|
|
WO/2017/150723A1 |
Algae that generates a sterol and a sterol production method that uses the algae. According to the present invention, a sterol is produced by culturing algae, such as strain AJ7867 (FERM BP-22304) and strains derived therefrom, that has ...
|
|
WO/2017/149091A1 |
The invention relates to a process for the preparation of 11 -methylene steroids through selective olefination of the ketone at position 11. The resulting products are useful intermediates in the preparation of several pharmaceutically a...
|
|
WO/2017/149052A1 |
The invention pertains to a process for producing a compound of formula (11) wherein R7 and R8 are each independently selected from H, halogen, alkyl, aryl, or alkylaryl, R42 is H or a protective group, R43 is H or R3, wherein R3 is a pr...
|
|
WO/2017/137931A1 |
The present application relates to amine salt of obeticholic acid. Specifically, the present application relates to (S)-α-methylbenzylamine and diethylamine salt of obeticholic acid. The present application also relates to a process for...
|
|
WO/2017/112904A1 |
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...
|
|
WO/2017/112909A1 |
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...
|
|
WO/2017/112902A1 |
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...
|
|
WO/2017/057460A1 |
Provided is a method for producing an organic compound, wherein the organic compound is an industrially useful compound, and a deodorization step, for removing from a reaction solution odorants that are generated in or remaining after a ...
|
|
WO/2017/041139A1 |
The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.
|
|
WO/2016/165496A1 |
Disclosed is method for preparing a deoxycholic acid or ester thereof or pharmaceutically acceptable salt thereof. The compound is suitable for removing fat deposition.
|
|
WO/2016/132355A1 |
Novel selective synthesis route to introduce primary alkyl groups on aromatic compounds is disclosed. The synthesis route is based on electrophilic aromatic substitutions of thionium ion species that are generated in-situ from aldehydes ...
|
|
WO/2016/126875A1 |
The automated synthesis of clinically relevant amounts of 16β-18F-fluoro-5α-dihydrotestosterone (18F-FDHT) using a commercially available radiosynthesizer. Synthesis was performed in 90 minutes with a decay-corrected radiochemical yiel...
|
|
WO/2016/054741A1 |
The invention relates to a microsphere composition comprising (a) a microsphere material; and (b) a lipidic liquid formulation comprising (i) an effective amount of a progestogen, and (ii) vitamin E or an analog of vitamin E, incorporate...
|
|
WO/2016/033549A2 |
Described here are substantially pure (17-?)-3-Oxoandrost-4-en-17-yl tridecanoate compositions, methods of their preparation and uses thereof
|
|
WO/2016/029888A1 |
The present invention provides amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use as medicaments for treating neuropsychiatric disorders associated with an ...
|
|
WO/2016/009442A1 |
The invention discloses a novel method for preparing neuromuscular blocking agents using aryl esters as a reagent of di-acylation as well as highly regioselective mono-acylation of androstane-diols.
|
